AstraZeneca Signs an Exclusive License Agreement with F-star Therapeutics for Novel STING Inhibitors
Shots:
- F-star is eligible to receive up front and near-term payments of ~$12M & will be eligible for ~$300M as development & sales milestone along with royalties. Payments received by F-star are subject to a CVR agreement in which a portion will be payable to F-star’s investors that were previously stockholders of Spring Bank
- AstraZeneca will obtain the global rights to research- develop & commercialize next-generation STING inhibitor compounds & get exclusive access to F-star’s novel preclinical STING inhibitors
- Additionally- F-star will retain rights to all STING agonists- currently in clinical development for patients with cancer
Ref: GlobeNewswire | Image: AstraZeneca
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com